<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00834301</url>
  </required_header>
  <id_info>
    <org_study_id>N0801</org_study_id>
    <nct_id>NCT00834301</nct_id>
  </id_info>
  <brief_title>An Open Label Trial to Evaluate the Effects of a Novel Renal Multivitamin on Inflammation and Other Biomarkers in Endstage Renal Disease Patients</brief_title>
  <official_title>An Open Label Trial to Evaluate the Effects of a Novel Renal Multivitamin on Inflammation and Other Biomarkers in Endstage Renal Disease Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nephrian</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nephrian</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine whether an ingestion of a new renal multivitamin
      supplement can have a beneficial effect on bone and mineral adn inflammation issues related
      to patients on dialysis.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2009</start_date>
  <completion_date type="Anticipated">September 2009</completion_date>
  <primary_completion_date type="Anticipated">September 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the efficacy and safety of a novel renal multivitamin on markers of bone and mineral metabolism in an ESRD population.</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess the efficacy and safety of a novel renal multivitamin on markers of inflammation in an ESRD population</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Hyperphosphatemia</condition>
  <condition>Inflammation</condition>
  <condition>Renal Disease</condition>
  <arm_group>
    <arm_group_label>Treatment Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Oral Multivitamin</intervention_name>
    <description>Oral Multivitamin</description>
    <arm_group_label>Treatment Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  End stage renal disease patients on dialysis for at least 90 days deemed to be at low
             risk by the investigator for being hospitalized or have concurrent infections

          -  Serum phosphorous level &gt; 5 mg/dl

          -  Stable phosphate binder regimen for 2 week prior to enrollment

          -  Stable dose of Vitamin D for 4 weeks prior to enrollment

          -  Stable calcimimetic dose for 4 week prior to enrollment

        Exclusion Criteria:

          -  patients who are pregnant

          -  patients who have pre existing thrombocytopenia defined as a platelet count of &lt;100 x
             109/L

          -  abnormal LFTs

          -  baseline CRP &gt; 15 g/dl

          -  known sensitivity to any of the active ingredients

          -  patients who are currently enrolled in a clinical trial, or who have been in a
             clinical trial in the last six months

          -  are currently taking any immunosuppressive medications
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ray Chow, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Nephrian</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Simi Valley Dialysis Center</name>
      <address>
        <city>Simi Valley</city>
        <state>California</state>
        <zip>93063</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kant Tucker, MD</last_name>
      <phone>805-433-7500</phone>
    </contact>
    <investigator>
      <last_name>Kant Tucker, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 2, 2009</study_first_submitted>
  <study_first_submitted_qc>February 2, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 3, 2009</study_first_posted>
  <last_update_submitted>February 2, 2009</last_update_submitted>
  <last_update_submitted_qc>February 2, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 3, 2009</last_update_posted>
  <responsible_party>
    <name_title>Ray Chow, Ph.D.</name_title>
    <organization>Nephrian Inc</organization>
  </responsible_party>
  <keyword>End Stage Renal Disease</keyword>
  <keyword>Inflammation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Hyperphosphatemia</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

